Literature DB >> 8937473

Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity.

L Cui1, R F Schinazi, G Gosselin, J L Imbach, C K Chu, R F Rando, G R Revankar, J P Sommadossi.   

Abstract

A group of enantiomeric nucleoside analogues with beta-D or beta-L configuration, which represent potential candidates for the treatment of hepatitis B virus (HBV) infection, were incubated in human hepatoblastoma HepG2 cells at concentrations between 0.1 and 10 microM for 4-14 days. Then the effect on mitochondrial DNA (mtDNA) content, lactic acid production, lipid droplet formation, and mitochondrial morphology were evaluated. No effect on lactic acid production was detected in cells treated with beta-L-2',3'-dideoxy-3'-thiacytidine (3TC), beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine (beta-L-FTC), beta-D-2',3'-dideoxy-5-fluoro-3'-thiacytidine (beta-D-FTC), racemic cis 2',3'-dideoxy-5-fluoro-3'thiacytidine [(+/-)-FTC], and 2,4-diamino-7-(2,3-dideoxy-2-fluoro-beta-D-arabinofuranosyl) pyrrolo[2',3'-d]pyrimidine (T70178), whereas a slight increase was associated with beta-D-2-hydroxymethyl-5-(2,6-diaminopurin-9-yl)-1,3-dixolane++ + (beta-D-DAPD) and 4-amino-7-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrrolo[2,3-d]pyrimi dine -5-thiocarboxamide (T70182) at 10 microM. A concentration-dependent increase in lactic acid production was observed in cells exposed to beta-D-2',3'-dideoxy-3'-thiacytidine [(+)-BCH-189], racemic cis 2',3'-dideoxy-3'-thiacytidine [(+/-)-BCH-189], beta-D-2',3'-dideoxy-5-fluorocytidine (beta-D-FddC), beta-L-2',3'-dideoxy-5-fluorocytidine (beta-L-FddC), beta-D-2-hydroxymethyl-5-(5-fluorocytosin-I-yl)-1,3,-dioxolane (beta-D-FDOC), 2,4-diamino-7-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) pyrrolo[2,3-d]pyrimidine (T70080), and 4-amino-7-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrrolo [2,3-d]pyrimidine (T70179). Inhibition on mtDNA content was demonstrated to be concentration-dependent with (+)-BCH-189, beta-D-FddC, and T70080, whereas 3TC, (+/-)-BCH-189, beta-L-FTC, beta-D-FTC, (+/-)-FTC, beta-L-FddC, beta-D-DAPD, T70178, T70179, and T70182 had no effect. beta-D-FDOC resulted in a marked inhibition of mtDNA synthesis at 10 microM but not at lower concentrations. Cells treated with 3TC, (+/-)-BCH-189, beta-L-FTC, beta-D-FTC, (+/-)-FTC, beta-L-FddC, beta-D-DAPD, T70178, T70179, and T70182 did not show morphological changes compared with the control. In contrast, increased cytoplasmic lipid droplets associated with a loss of cristae in mitochondria were detected in cells treated with either beta-D-FDOC, beta-D-FddC, or T70080, (+)-BCH-189 treatment resulted in loss of cristae in mitochondria. In summary, 3TC, beta-L-FTC, beta-D-FTC, (+/-)-FTC, beta-D-DAPD, T70178, and T70182 exhibited a relatively safe profile, supporting their further development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8937473     DOI: 10.1016/s0006-2952(96)00562-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  18 in total

1.  Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogues.

Authors:  Lieven J Stuyver; Stefania Lostia; Marjorie Adams; Judy S Mathew; Balakrishna S Pai; Jason Grier; Phillip M Tharnish; Yongseok Choi; Youhoon Chong; Hyunah Choo; Chung K Chu; Michael J Otto; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 2.  Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

3.  In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.

Authors:  R Chin; T Shaw; J Torresi; V Sozzi; C Trautwein; T Bock; M Manns; H Isom; P Furman; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 4.  Development of resistance and perspectives for future therapies against hepatitis B infections: lessons to be learned from HIV.

Authors:  K Deres; H Rübsamen-Waigmann
Journal:  Infection       Date:  1999       Impact factor: 3.553

5.  Pharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys.

Authors:  L T Martin; E Cretton-Scott; R F Schinazi; X J Zhou; H M McClure; C Mathe; G Gosselin; J L Imbach; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

6.  Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine.

Authors:  Adrian S Ray; Brenda I Hernandez-Santiago; Judy S Mathew; Eisuke Murakami; Carey Bozeman; Meng-Yu Xie; Ginger E Dutschman; Elizabeth Gullen; Zhenjun Yang; Selwyn Hurwitz; Yung-Chi Cheng; Chung K Chu; Harold McClure; Raymond F Schinazi; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

7.  Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.

Authors:  Raymond F Schinazi; Leda Bassit; Marcia M Clayton; Bill Sun; James J Kohler; Aleksandr Obikhod; Alla Arzumanyan; Mark A Feitelson
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

Review 8.  Emtricitabine: an antiretroviral agent for HIV infection.

Authors:  Lynne M Bang; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Selwyn J Hurwitz; Raymond F Schinazi
Journal:  Drug Discov Today Technol       Date:  2012

10.  Efficacies of beta-L-D4A against Hepatitis B virus in 2.2.15 cells.

Authors:  Lin-Lin Gao; Xiao-Yan Wang; Ju-Sheng Lin; Ying-Hui Zhang; Yan Li
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.